Format

Send to

Choose Destination
Lancet Infect Dis. 2014 Apr;14(4):267-9. doi: 10.1016/S1473-3099(14)70028-3.

Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines.

Author information

1
Division of Infection and Immunity, University College London, London, UK; Department of Medical Microbiology, University College London Hospitals NHS Trust, London, UK.
2
Henry M Jackson Foundation-Division of AIDS, TB Clinical Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
3
Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; CAST, Karolinska University Hospital, Stockholm SE-14186, Sweden. Electronic address: markus.maeurer@ki.se.
PMID:
24670623
DOI:
10.1016/S1473-3099(14)70028-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center